**Index**

*Note: Page numbers of article titles are in **boldface** type.*

**A**

**Abscess(es)**
- brain, 615–618. See also *Brain abscess.*
- intra-abdominal sepsis–related, management of, percutaneous drainage vs. surgery in, 596–597
- intracardiac, acute infective endocarditis and, 656–657

**Acute infective endocarditis,** 643–664. See also *Infective endocarditis, acute.*

**Anidulafungin,** for candidal bloodstream infections in ICU, 637

**Antibiotic(s).** See also *Antimicrobial stewardship.*
- broad-spectrum, in severe community-acquired infections, 598
- for acute infective endocarditis, 648
- for brain abscess, 617
- for intra-abdominal sepsis, initiation of, 595–596
- for meningitis, 613–614
- for septic shock and severe sepsis, 487–489
- for severe CAP, 508–512
- for SSTIs, 573–574
  - methicillin-resistant *Staphylococcus aureus*–related, 573–577
- for VAP
  - initial, 523
  - prescription at bedside, 523–528. See also *Ventilator-associated pneumonia (VAP), management of, antibiotics in.*

in health care–associated intra-abdominal infections, regimens for, 599–601
- in ICU, 683–702
  - described, 683–684
  - new agents, 665–681. See also specific agents.
    - ceftaroline, 665–666
    - ceftobiprole, 666–667
    - dalbavancin, 668
    - iclaprim, 671
    - isavuconazole, 672
    - oritavancin, 669–670
    - telavancin, 670–671
    - optimizing use of, 684–685
    - programs for, 685–687
  - patient safety with, 685
  - resistance to, 684–685

**Antibiotic resistance,** in ICU, 684–685

**Antigenemia, CMV,** fever in ICU patients due to, 479

**Antimicrobial agents.** See *Antibiotic(s).*
Antimicrobial stewardship, 683–702
  enhancing of, institutional program for, development of, 686–687
  hospital-based, 685
  interventional strategy for, 686
  outcome measurements, 696–697
  potential barriers to, 690–691
  preauthorization strategy, 690
  primary program strategy, supplemental programs to, 691–696
    adaptation of locally customized, published guidelines, 695–696
    computer-assisted decision support programs, 694–695
    educational efforts, 694
    formulary interventions, 691–692
    pharmacodynamic dose optimization, 692–694
  process measurements, 696–697
  prospective audit and feedback strategy, 687–689
  teams members in, 687
Aspergillosis, pulmonary, invasive, in ICU, 625–630

B
Bacillus(i), gram-negative, acute infective endocarditis due to, 656
Bacterial meningitis, 609–611
Biomarker(s)
  in approach to febrile patients in ICU, 480
  in septic shock and severe sepsis management, 495
Blood products, in septic shock and severe sepsis management, administration of, 493
Bloodstream infections
  candidal, in ICU, 630–637. See also Candidal bloodstream infections.
  in ICU, 557–569
    CLABSI, 710–711
    community-acquired, 563–564
    definitions related to, 557–558
    epidemiology of, 710
    health care–associated, 564–566
      epidemiology of, 564
      microbiology of, 564–565
      prognosis of, 566
      sources of, 565
      systemic response to, 565–566
    hospital-acquired, 558–562
      epidemiology of, 558–559
      microbiology of, 559–560
      prognosis of, 562
      risk factors for, 559
      sources of, 561
      systemic response to, 561–562
    prevention of, 710–711
    risk factors for, 710
    treatment of, 566
    types of, 557–558
Brain abscess, 615–618
  causes of, 615–616
  clinical manifestations of, 616
  diagnosis of, 616–617
  epidemiology of, 615–616
  treatment of, 617–618

C
Candidal bloodstream infections, in ICU, 630–637
  epidemiology of, 630–631
  prevention of, 633–634
  risk factors for, 631–633
  treatment of, 634–637
    echinocandins in, 636
    presumptive, 633–634
Cardiovascular devices, infective endocarditis related to, 650–651
Caspofungin, for candidal bloodstream infections in ICU, 636
Catheter(s)
  in septic shock and severe sepsis management, 489
  infections related to, fever in ICU patients due to, 477–478
CDC. See Centers for Disease Control and Prevention (CDC).
Ceftaroline, in ICU, 665–666
Ceftobiprole, in ICU, 666–667
Centers for Disease Control and Prevention (CDC), on infection definitions, 558
Central nervous system (CNS), abnormalities of, in immunocompromised hosts with
  infection in ICU, 543–550
Central nervous system (CNS) infections, 609–623. See also specific infections, e.g.,
  Meningitis.
    brain abscess, 615–618
    fever in ICU patients due to, 479
    meningitis, 609–615
    subdural empyema, 618
    treatment of, antibiotics in, 613–614
CHF. See Congestive heart failure (CHF).
Cholestyramine, for Clostridium difficile infection in ICU, 733
CLABSI, in ICU, 710–711
Clostridium difficile infection, in ICU, 711–712, 727–743
  clinical manifestations of, 730
  diagnosis of, 730–731
  epidemiology of, 711–712, 728–729
  pathogenesis of, 728–729
  prevention of, 712, 735
  risk factors for, 712, 729–730
  treatment of, 731–734
    cholestyramine in, 733
    colestipol in, 733
    failure with, 734
    IVIG in, 733–734
    metronidazole in, 732
Clostridium (continued)
  OPT-80 in, 733
  probiotics in, 733
  relapse following, 734–735
  teicoplanin in, 733
CMV. See Cytomegalovirus (CMV).
CNS. See Central nervous system (CNS).
Colestipol, for Clostridium difficile infection in ICU, 733
Community-acquired bloodstream infection, in ICU, 563–564
Community-acquired infections, severe, management of, broad-spectrum antibiotics in, 598
Community-acquired pneumonia (CAP)
described, 503
epidemiology of, 504
prevalence of, 504
severe, 503–520
  epidemiology of, 504
  ICU admission for, criteria for, 505–508
  management of, 508–514
    antibiotics in, 508–512
    drotrecogin alfa in, 513–514
    lung protective-ventilation strategy in, 514
    non-antimicrobial agents in, 512–514
    recombinant human activated protein C in, 513–514
    systemic steroids in, 512–514
  microbiology of, 504–505
  prevalence of, 504
  severity assessment in, 505–508
Community-acquired pneumonia (CAP) bundle, 514
Computed tomography (CT), in acute infective endocarditis evaluation, 648
Congestive heart failure (CHF), acute infective endocarditis and, 656–657
Corticosteroid(s), in septic shock and severe sepsis management, 491
CT. See Computed tomography (CT).
Cytomegalovirus (CMV) antigenemia, fever in ICU patients due to, 479

D
Dalbavancin, in ICU, 668
Diabetic foot infections, SSTIs due to, 585–586
Diarhea
  in ICU, 727
    nosocomial, fever in ICU patients due to, 478
Drotrecogin alfa, in severe CAP management, 513–514

E
Echinocandins, for candidal bloodstream infections in ICU, 636
Echocardiography, in acute infective endocarditis evaluation, 646–648
Embolism, acute infective endocarditis and, 657
Empyema, subdural, 618
Endocarditis
- defined, 643
- prosthetic valve, 650

Enterococcus(i), acute infective endocarditis due to, 656

Environment, hospital, nosocomial infections in ICU related to, 705–708

F

Febrile patients, in ICU, 471–484. See also Fever, in ICU patients.
- approach to
  - biomarkers in, 480
  - initial, 479–480

Fever
- characteristics of, 473–474
- defined, 472
- in ICU patients, 471–484
  - approach to
    - biomarkers in, 480
    - initial, 479–480
  - causes of, 474–479
    - catheter-related infections, 477–478
    - CMV antigenemia, 479
    - CNS infections, 479
    - fungal infections, 479
    - infectious, 477–479
    - intra-abdominal infections, 479–480
    - noninfectious, 474–477
    - nosocomial diarrhea, 478
    - respiratory system infections, 477
    - sinusitis, 478
    - surgical site infections, 479–480
    - urinary tract infections, 479
  - organ responses to, 473
  - pathogenesis of, 473–474
  - physiology of, 472–473

Fluid resuscitation, in intra-abdominal sepsis management, 595

Foot infections, diabetic, SSTIs due to, 585–586

Fungal infections
- fever in ICU patients due to, 479
  - in ICU, 625–642
    - candidal bloodstream infections, 630–637. See also Candidal bloodstream infections.
    - invasive pulmonary aspergillosis, 625–630

Fungal meningitis, 611

H

Hand colonization, nosocomial infections in ICU related to, 706

Hand hygiene, nosocomial infections in ICU related to, 705–706

Health care personnel, nosocomial infections in ICU related to, 705
Health care–associated bloodstream infection, in ICU, 564–566. See also Bloodstream infections, in ICU, health care–associated.

Health care–associated infections described, 595
  intra-abdominal sepsis and, management of antibiotics in, 599–601
  microbiology in, 599

HIV-1 infection. See Human immunodeficiency virus-1 (HIV-1) infection.

Hospital environment, nosocomial infections in ICU related to, 705–708

Hospital-acquired bloodstream infection, in ICU, 558–562. See also Bloodstream infections, in ICU, hospital-acquired.

Human immunodeficiency virus-1 (HIV-1) infection, in immunocompromised hosts with infection in ICU, 550–551

Hyperbaric oxygen therapy, in NSTIs management, 584

Hyperglycemia, nosocomial infections in ICU related to, 704–705

I

Iatrogenic immunosuppression, in immunocompromised hosts with infection in ICU, management of, 551

Iclaprim, in ICU, 671

ICU. See Intensive care unit (ICU).

Immunocompromised hosts, infection in general truths about, 536–537 in ICU, 535–556
  clinical presentations of, 540–551
  CNS–related, 543–550
  HIV-1 infection, 550–551
  pulmonary infiltrates, 541–543
  respiratory insufficiency/failure, 541–543
  emerging trends for, 552
  iatrogenic immunosuppression in, management of, 551
  initial assessment of, 537–540
  prevalence of, 535–536
  protective isolation and special precautions for, 551–552

Immunoglobulin, intravenous
  for Clostridium difficile infection in ICU, 733–734
  in NSTIs management, 584

Immunosuppression, iatrogenic, in immunocompromised hosts with infection in ICU, management of, 551

Infection(s). See also specific types.
  bloodstream, in ICU, 557–569. See also Bloodstream infections, in ICU.
  catheter-related, fever in ICU patients due to, 477–478
  CNS, 609–623
  diabetic foot, SSTIs due to, 585–586
  fungal
    fever in ICU patients due to, 479
    in ICU, 625–642. See also Fungal infections, in ICU.
  in ICU, prevention of, 703–725. See also specific types and Intensive care unit (ICU), infections in, prevention of.
in immunocompromised hosts, in ICU, 535–556. See also Immunocompromised hosts, infection in, in ICU.
intra-abdominal, fever in ICU patients due to, 479–480
nosocomial, in ICU, 703–712. See also Nosocomial infections, in ICU.
of respiratory system, fever in ICU patients due to, 477
surgical site, fever in ICU patients due to, 479–480
urinary tract, fever in ICU patients due to, 479

Infective endocarditis
acute, 643–664
approach to patient with, 646–651
CHF due to, 656–657
complications of, 656–657
demographics of, 644–645
diagnosis of, 646–648
criteria in, 646, 647
CT in, 648
echocardiography in, 646–648
laboratory tests in, 646
MRI in, 648
patient history in, 646
physical examination in, 646
embolism due to, 657
epidemiology of, 644–646
in ICU, 645–646
intracardiac abscess due to, 656–657
mortality associated with, 657
organisms causing, 651, 656
pathogenesis of, 643–644
prevention of, 657–658
risk factors for, 644–645
treatment of, 652–655
antibiotics in, 648
surgical, 648–649

cardiocascular device–related, 650–651
right-sided, 649–650

Insulin, intravenous, in septic shock and severe sepsis management, 492–493

Intensive care unit (ICU)
antibiotics in, 683–702. See also Antibiotic(s), in ICU.
bloodstream infection in, 557–569. See also Bloodstream infection, in ICU.
Clostridium difficile infection in, 727–743. See also Clostridium difficile infection, in ICU.
diarrhea in, 727
febrile patients in, 471–484
approach to
biomarkers in, 480
initial, 479–480
fungal infections in, 625–642. See also Fungal infections, in ICU.
immunocompromised hosts with infection in, approach to, 535–556. See also Immunocompromised hosts, infection in, in ICU.
infections in. See also specific infections.
antibiotic resistance to, 712–713
prevention of, 703–725
Intensive (continued)

- Infective endocarditis in, 645–646
- Severe CAP admission to, criteria for, 505–508

Intra-abdominal infections, fever in ICU patients due to, 479–480

Intra-abdominal sepsis

- Community-acquired, severe, management of, broad-spectrum antibiotics in, 598
- Complicated, described, 594
- Diagnosis of, initial, 595–596
- Health care–associated infections described, 595
- Management of, antibiotics in, regimens, 599–601
- High risk, described, 594
- Management of, 593–608
  - Abscess-related, percutaneous drainage vs. surgery, 596–597
  - Altered strategies in, 593–594
  - Antibiotics in, initiation of, 595–596
  - Duration of therapy in, 601–602
  - Fluid resuscitation in, 595
  - Microbiology laboratory in, 597–598
  - Pharmacokinetic and pharmacodynamic considerations in, 601
  - Source control in, procedures in, 596
  - Terminology related to, 594–595
- Severe, management of, surgical, 597
- Severity of, described, 594

Intracardiac abscess, acute infective endocarditis and, 656–657

Intravenous immunoglobulin (IVIG)

- For *Clostridium difficile* infection in ICU, 733–734
- In NSTIs management, 584

Invasive pulmonary aspergillosis, in ICU, 625–630

Isavuconazole, in ICU, 672

Isolation measures, nosocomial infections in ICU related to, 708

IVIG. See *Intravenous immunoglobulin (IVIG)*.

L

Lung protective-ventilation strategy, in severe CAP management, 514

M

Magnetic resonance imaging (MRI), in acute infective endocarditis evaluation, 648

Malnutrition, nosocomial infections in ICU related to, 704

Mechanical ventilation, in septic shock and severe sepsis management, 493–494

Meningitis, 609–615

- Bacterial, 609–611
- Clinical manifestations of, 611–612
- Diagnosis of
  - Laboratory, 612–613
  - Physical examination in, 611–612
  - Vs. early treatment, 613
- Epidemiology of, 609–611
- Fungal, 611
parasitic, 611
  treatment of, 613–615
    adjuvant therapy in, 614
    complications of, management of, 614–615
    supportive care in, 614
    vs. diagnosis, 613
  viral, 610–611
Meningoencephalitis, 610
Methicillin-resistant Staphylococcus aureus, SSTIs due to, management of, antibiotics in, 573–577
Metronidazole, for Clostridium difficile infection in ICU, 732
Micafungin, for candidal bloodstream infections in ICU, 636–637
Microbiology, in health care–associated infections management, 599
MRI. See Magnetic resonance imaging (MRI).

N
Necrotizing soft tissue infections (NSTIs), 581–584
  described, 581
  diagnosis of, aids in, 581–582
    imaging in, 582–583
    management of, novel agents in, 584
    microbiology of, 583
Nosocomial diarrhea, fever in ICU patients due to, 478
Nosocomial infections, in ICU, 703–712. See also specific types, e.g., Ventilator-associated pneumonia (VAP).
  bloodstream infections, 710–711
  Clostridium difficile infection, 711–712
  risk factors for, 703–708
  UTIs, 711
  ventilator-associated pneumonia, 708–710
NSTIs. See Necrotizing soft tissue infections (NSTIs).
Nutrition
  in septic shock and severe sepsis management, 494
  supplemental, nosocomial infections in ICU related to, 704

O
OPT-80, for Clostridium difficile infection in ICU, 733
Oritavancin, in ICU, 669–670

P
Parasitic meningitis, 611
Patient rooms, nosocomial infections in ICU related to, 706–707
Patient screening, nosocomial infections in ICU related to, 707
Pneumonia(s)
  ventilator-associated. See Ventilator-associated pneumonia (VAP).
Probiotics, for Clostridium difficile infection in ICU, 733
Prosthetic valve endocarditis, 650
Protein C, recombinant activated
  in septic shock and severe sepsis management, 491–492
  in severe CAP management, 513–514
Pulmonary aspergillosis, invasive, in ICU, 625–630
Pulmonary infiltrates, in immunocompromised hosts with infection in ICU, 541–543
Pyomyositis, 584–585

R
Recombinant activated protein C
  in septic shock and severe sepsis management, 491–492
  in severe CAP management, 513–514
Respiratory insufficiency/failure, in immunocompromised hosts with infection in ICU, 541–543
Respiratory system, infections of, fever in ICU patients due to, 477

S
Sepsis
  intra-abdominal. See Intra-abdominal sepsis.
  severe
    diagnosis of, 487
    initial assessment of, 485–487
    management of, 484–500
      antibiotics in, 487–489
      biomarkers in, 495
      blood products in, administration of, 493
      catheters in, 489
      corticosteroids in, 491
      intravenous insulin in, 492–493
      mechanical ventilation in, 493–494
      nutrition in, 494
      prophylactic measures in, 494–495
      recombinant activated protein C in, 491–492
      source control in, 490–491
      vasoactive therapy in, 489–490
    treatment of, 486
Septic shock
  diagnosis of, 487
  initial assessment of, 485–487
  management of, 484–500
    antibiotics in, 487–489
    biomarkers in, 495
    blood products in, administration of, 493
    catheters in, 489
    corticosteroids in, 491
    intravenous insulin in, 492–493
    mechanical ventilation in, 493–494
    nutrition in, 494
    prophylactic measures in, 494–495
    recombinant activated protein C in, 491–492
source control in, 490–491
vasoactive therapy in, 489–490
treatment of, 486

Severe CAP. See Community-acquired pneumonia (CAP), severe.

Shock, septic. See Septic shock.

Sinusitis, fever in ICU patients due to, 478

Skin and soft tissue infections (SSTIs), 571–591
causes of
  diabetic foot infections, 585–586
  methicillin-resistant Staphylococcus aureus, management of, antibiotics in, 573–577
classification of, 571–573
complicated vs. uncomplicated, 572
described, 571
epidemiology of, 574–577
management of
  antibiotics in, 573–574
    de-escalation in, 577–581
    pathogen identification with, 577–581
  source control in, 577
microbiology of, 574–577
necrotizing, 581–584
  vs. non-necrotizing, early diagnosis and differentiation, 571–573
pyomyositis, 584–585
types of, 581–586

SSTIs. See Skin and soft tissue infections (SSTIs).

Staphylococcus(), coagulase-negative, acute infective endocarditis due to, 651

Staphylococcus aureus
  acute infective endocarditis due to, 651
    methicillin-resistant, SSTIs due to, management of, antibiotics in, 573–577

Steroid(s), systemic, in severe CAP management, 512–514

Streptococcus(), acute infective endocarditis due to, 651, 655

Subdural empyema, 618

Supplemental nutrition, nosocomial infections in ICU related to, 704

Surgical site infections, fever in ICU patients due to, 479–480

T

Teicoplanin, for Clostridium difficile infection in ICU, 733

Telavancin, in ICU, 670–671

U

Urinary tract infections (UTIs), in ICU, 711
  fever related to, 479

UTIs. See Urinary tract infections (UTIs).
V

Vacuum-assisted wound closure, in NSTIs management, 584
VAP. See Ventilator-associated pneumonia (VAP).
Vasoactive therapy, in septic shock and severe sepsis management, 489–490
Ventilation, mechanical, in septic shock and severe sepsis management, 493–494
Ventilator-associated pneumonia (VAP)
   diagnosis of, tests in, 521–522
   in ICU, 708–710
      epidemiology of, 708
      prevalence of, 708
      prevention of, 709–710
      risk factors for, 708–709
management of, 521–533
   antibiotics in
      combination vs. monotherapy, 523–524
      drug structure in, 527–528
      duration of, 529–530
      host factors in, 527
      initial, 522–523
      pharmacokinetic-pharmacodynamic considerations in, 526–528
      prescription at bedside, 523–528
      regimen for, 524–526
      empiric regimen in, evaluation of clinical response and adjustment of, 528–530
Viral meningitis, 610–611
Voriconazole, for candidal bloodstream infections in ICU, 635–636

W

Wound closure, vacuum-assisted, in NSTIs management, 584